NRG/RTOG 9601长期结果:挽救性前列腺床放疗联合或不联合抗雄药物治疗的随机试验
NRG/RTOG 9601是一项双盲安慰剂对照随机试验,纳入760例根治性前列腺切除术后pT3N0或pT2N0切缘阳性且PSA 0.2–4.0 ng/mL的患者,比较挽救性前列腺床放疗(64.8 Gy/36次)联合或不联合24个月比卡鲁胺150 mg/d的长期疗效。中位随访18.9年显示,联合抗雄药物显著改善18年总生存(53% vs 43%)、降低前列腺癌死亡(18% vs 28%)和转移(22% vs 31%)。
要点
- 联合治疗降低18年前列腺癌死亡(18% vs 28%)和转移发生率(22% vs 31%)。
- 总生存绝对获益从12年的5%增至18年的9.8%。
核心结论
- 挽救性放疗期间及之后联合24个月抗雄药物治疗可显著改善长期总生存、降低前列腺癌转移发生率和前列腺癌死亡。
研究设计与样本
- 1998至2003年纳入760例根治性前列腺切除术后pT3N0或pT2N0切缘阳性且PSA 0.2–4.0 ng/mL的患者,随机接受放疗+安慰剂或放疗+抗雄药物(比卡鲁胺150 mg/d共24个月),放疗剂量64.8 Gy/36次。
- 双盲、安慰剂对照随机试验,主要终点为总生存,采用Kaplan-Meier法估计。
关键数值与推荐
- 入组条件:根治性前列腺切除术后pT3N0或pT2N0伴切缘阳性,PSA 0.2–4.0 ng/mL。
- 干预方案:前列腺床放疗64.8 Gy/36次,联合比卡鲁胺150 mg每日一次共24个月。
临床怎么用
- 对于根治性前列腺切除术后PSA复发(0.2–4.0 ng/mL)且具备pT3N0或pT2N0切缘阳性特征的患者,可考虑在挽救性前列腺床放疗期间及之后联合24个月比卡鲁胺150 mg/d以改善长期生存并降低转移和死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Salvage radiation therapy (RT) is used in men with prostate cancer (PC) recurrence following radical prostatectomy signaled by a persistent or delayed elevation in prostate specific antigen. It was previously reported that the use of antiandrogen therapy (AAT) with RT improved cancer control and overall survival (OS). Long-term follow-up results are presented in this study. METHODS AND MATERIALS: From 1998 to 2003, 760 eligible postradical prostatectomy patients with stage pT3N0 or with pT2N0 and positive margins and prostate specific antigen from 0.2 to 4.0 ng/mL were randomly assigned on a double-blinded, placebo-controlled trial of RT + placebo versus RT + AAT (24 months of bicalutamide, 150 mg daily) during and after RT (64.8 Gy in 36 fractions prostate bed). The primary endpoint was OS estimated using Kaplan-Meier method. Time to PC death and metastatic PC (competing risk of death without an event) was estimated using cumulative incidence. The hazard ratio (HR) was obtained using Cox models (OS) and subdistribution HRs (sHRs) used the Fine-Gray model (time to PC death and metastatic PC). RESULTS: Median follow-up for surviving patients was 18.9 years. OS at 18 years was 53% (95% CI, 47%-58%) for RT + AAT and 43% (95% CI, 38%-49%) for RT + placebo (adjusted HR = 0.82; 95% CI, 0.67-1.00; 1-sided P = .025). The 18-year incidence of centrally reviewed PC deaths was 18% (95% CI, 14%-22%) RT + AAT and 28% (95% CI, 23-33%) RT + placebo (unadjusted sHR = 0.63; 95% CI, 0.46-0.84; 2-sided P = .002). The 18-year incidence of metastatic PC was 22% (95% CI, 18-26%) and 31% (95% CI, 26-36%) for AAT and placebo arms, respectively (unadjusted sHR = 0.62; 95% CI, 0.46-0.83; 2-sided P = .001). CONCLUSIONS: Long-term results of 24-month duration AAT during and after salvage RT are consistent with the primary report with significantly improved long-term OS, reduced incidence of metastatic PC, and PC death for RT + AAT. In comparison with previous reports, the improvement in OS with AAT has risen from 5% at 12 years to 9.8% at 18 years.
引用
- Lukka HR, Pugh SL, Shipley WU, et al. Long-Term Results of NRG/RTOG 9601, a Randomized Trial of Radiation With or Without Antiandrogens in Patients Receiving Salvage Prostate Bed Radiation Therapy Postprostatectomy. Int J Radiat Oncol Biol Phys. 2025. PMID: 40752653. doi:10.1016/j.ijrobp.2025.07.1416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。